A Phase II Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination with Anti-PD-(L)1 Therapy in Subjects with NSCLC as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy
Principal Investigator
Timothy A. McCarthy, MDLocations
Fairfax Office
Gainesville Office
Arlington Office
Alexandria Office
Loudoun Office
Learn More About This Trial
Other Relevant Trials
Phase 1b/2 Study of TAK-981 Plus Pembrolizumab to Evaluate the Safety, Tolerability, and Antitumor Activity of the Combination in Patients With Select Advanced or Metastatic Solid Tumors
Principal Investigator
Alexander I. Spira, MD, PhD, FACP“A Phase 1 first in human study evaluating safety and efficacy of ABBV-637 as either monotherapy or in combination in adult subjects with relapsed and refractory solid tumors”
